Comparative Pharmacology
Head-to-head clinical analysis: DARVOCET N 50 versus DURAGESIC 100.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DARVOCET N 50 versus DURAGESIC 100.
DARVOCET-N 50 vs DURAGESIC-100
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a weak mu-opioid receptor agonist; it also binds to sigma receptors. Acetaminophen inhibits prostaglandin synthesis via COX-1 and COX-2, thereby reducing pain and fever.
Pure opioid agonist that binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins to inhibit pain transmission. Also interacts with kappa and delta receptors. Therapeutic effects include analgesia, sedation, and euphoria.
1 tablet (propoxyphene 50 mg, acetaminophen 300 mg) orally every 4 hours as needed for pain, not to exceed 6 tablets per day.
Transdermal patch; initial dose based on prior opioid use: for opioid-naive patients, 12 mcg/h every 72 hours; for opioid-tolerant patients, convert using equianalgesic tables; maximum dose 100 mcg/h per patch; apply to non-irritated, non-irradiated skin on chest, back, flank, or upper arm.
None Documented
None Documented
Acetaminophen: 1.5-3 hours (therapeutic); 4-6 hours in overdose due to saturation of metabolism. Propoxyphene: 6-12 hours (parent); norpropoxyphene: 30-36 hours (active metabolite, accumulates with repeated dosing).
Terminal elimination half-life approximately 20–27 hours after transdermal system removal (range 13–25 hours in healthy adults; prolonged in elderly, hepatic impairment, and cachexia).
Acetaminophen: renal (90-100% as metabolites within 24h; 2-4% unchanged). Propoxyphene: renal (25-30% unchanged; metabolites) and biliary/fecal (significant enterohepatic circulation).
Renal (primarily as metabolites, <10% unchanged fentanyl); fecal (about 9% of dose).
Category C
Category C
Opioid Analgesic
Opioid Analgesic